“It was easy, fun, and I’d do it all over again.” I know those are not the typical words used by someone who just finished participating in a research study, especially one focused on ALS. But that’s exactly how I felt last week when I pressed the submit button…
Having possible symptoms of amyotrophic lateral sclerosis (ALS) increases the chances of getting an ALS diagnosis by nearly five times, but getting diagnosed is more likely for people in urban areas, who have greater access to specialized care, a U.S. study shows. People in rural areas are diagnosed at…
While women with amyotrophic lateral sclerosis (ALS) see a faster functional decline, men have shorter survival times, mostly due to more rapid weight loss and lung function worsening, a study shows. The findings highlight the importance of considering sex-specific differences when studying the mechanisms leading to ALS and when…
When I look back at photos from when my late husband, Jeff, was living with ALS — something I do often to find inspiration for this column — I’m struck by how many of our happier memories took place outdoors, even in the advanced stages of Jeff’s illness.
The Gary E. Shealy Memorial ALS Clinic in Tennessee has received a $75,000 grant from the ALS Association to support expanding its clinical care services for people with amyotrophic lateral sclerosis (ALS). The clinic at East Tennessee State University (ETSU) Health is the only one in the state that…
A decade ago, I purchased a fireproof lockbox to secure important papers, such as birth certificates, Social Security cards, and passports. I also stored several necklaces that my husband, Todd, had given to me, along with two watches he’d worn before he got ALS. Over the years, I added…
Treatment with Qalsody (tofersen) in the real world slowed disease progression in people with amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations, a small study reports. It also stabilized patients’ quality of life and lowered levels of nerve damage-related biomarkers, which is consistent with clinical trial data that…
A double-blind Phase 2 clinical trial that will test Corcept Therapeutics’ oral cortisol modulator dazucorilant against a placebo in people with amyotrophic lateral sclerosis (ALS) is now fully enrolled, the company announced in a press release. Called DAZALS (NCT05407324), the trial involves 249 adults with sporadic…
For those of us living with ALS, every day can have a stressful event. The key, I believe, is to get through the event and, if possible, remember it later with humor. Even in a parking lot. “Let’s circle the parking lot one more time,” my agitated husband said.
Treatment with NurOwn (debamestrocel), which BrainStorm Cell Therapeutics is developing for amyotrophic lateral sclerosis (ALS), may bring about changes in biomarkers of inflammation and neurodegeneration that predict clinical outcomes. The findings come from the Phase 3 trial (NCT03280056) that tested NurOwn against a placebo in 189 adults with rapidly…
Get regular updates to your inbox.